What Rappta Therapeutics does

Rappta Therapeutics Oy is a late preclinical-stage biopharmaceutical company headquartered in Helsinki, Finland, with team operations spanning Finland and the United States. The company is developing first-in-class molecular glue small molecules that reactivate Protein Phosphatase 2A (PP2A), a key tumor suppressor enzyme whose inactivation is implicated in multiple cancers including KRAS-driven tumors, MEK inhibitor-resistant cancers, castration-resistant prostate cancer, and MYC-driven cancers. Rappta's compounds act as molecular glues that enable the three subunits of PP2A (scaffolding A, catalytic C, and regulatory B) to bind together correctly, reforming the active enzyme complex to negatively regulate oncogenic signaling pathways. The platform is anchored by proprietary high-resolution PP2A-Drug complex structural data and a tool set developed by founding scientists who are pre-eminent PP2A researchers with seminal publications in Cell, J Clin Invest, Sci Transl Med, and Cancer Res.

The company's lead asset, RPT04402, was out-licensed globally to SpringWorks Therapeutics in January 2025 under a deal in which SpringWorks paid $13M upfront and assumed responsibility for global development and commercialization, including filing an IND application by end of 2025. Rappta retains eligibility for clinical, regulatory, and commercial milestone payments plus tiered royalties on net sales. The company generates revenue exclusively through licensing agreements and has no commercialized products. The underlying PP2A reactivation platform has stated potential to address a broader range of human diseases beyond oncology, given PP2A's central role in protein phosphorylation regulation.

Rappta was founded in 2020 and has raised approximately $10.6M in equity financing from Advent Life Sciences, Novartis Venture Fund, and Novo Holdings. Its go-to-market model is partnership-driven: Rappta develops and out-licenses proprietary molecular glue compounds, while larger pharmaceutical partners fund late-stage development and commercialization. The company's scientific credibility rests on the deep domain expertise of its founding team and the proprietary structural and biological understanding of the PP2A target, which has historically been considered very difficult to drug pharmacologically.

Name

Rappta Therapeutics

Legal name

Rappta Therapeutics Oy

Website

https://rappta-therapeutics.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Rappta Therapeutics is a late preclinical-stage biopharmaceutical company developing first-in-class molecular glue small molecules that reactivate the PP2A tumor suppressor for cancer treatment, with lead asset RPT04402 out-licensed globally to SpringWorks Therapeutics in January 2025.

Ownership category

akta.pro rank

Product category

Oncology Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Lead Optimization & Preclinical Candidate Selection (HLAIALAB)

akta.pro secondary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

Keywords

• Molecular glue therapeutics
• PP2A reactivation
• Oncology drug discovery
• Tumor suppressor activators
• Cancer small molecules

Headquarters

HQ city

Helsinki

HQ country

Finland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Licensing and Milestone Payments: Rappta generates revenue through licensing agreements with pharmaceutical partners. Under the SpringWorks partnership, Rappta received $13 million upfront and is eligible for clinical, regulatory, and commercial milestone payments plus tiered royalties on net sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Rappta Therapeutics develops a proprietary molecular glue-based technology platform that reactivates Protein Phosphatase 2A (PP2A), a key tumor suppressor enzyme. Its lead product candidate, RPT04402, is a first-in-class molecular glue designed to enable the three PP2A subunits to bind together, reforming the active PP2A complex to target oncogenic substrates in cancer. The company primarily monetizes this through licensing deals with larger pharmaceutical partners who handle downstream development and commercialization.

Product overview

Rappta Therapeutics is a late preclinical stage biopharmaceutical company developing a proprietary molecular glue technology platform centered on PP2A (Protein Phosphatase 2A) reactivation. The core product, RPT04402, is a first-in-class molecular glue therapeutic candidate for cancer treatment. The PP2A Reactivation Technology Platform enables the development of anti-cancer molecules that restore PP2A enzyme activity by facilitating subunit binding, addressing a historically difficult-to-target tumor suppressor. The company has leveraged high-resolution PP2A-drug complex structures to develop an entire series of compounds with potential for treating a broad range of human diseases beyond cancer.

Differentiator

Problem solved

Functional benefit

Products and services

• RPT04402 RPT04402 is Rappta's lead first-in-class molecular glue therapeutic candidate targeting Protein Phosphatase 2A (PP2A) for cancer treatment. It acts as a small-molecule glue that allows the three subunits of PP2A (scaffolding A, catalytic C, regulatory B) to bind together, driving PP2A complex reformation to target oncogenic substrates. The candidate is being advanced through a global license partnership with SpringWorks Therapeutics, intended for oncology indications including KRAS-driven tumors, MEK inhibitor-resistant cancers, castration-resistant prostate cancer, and MYC-driven cancers.
• PP2A Reactivation Technology Platform Rappta's proprietary molecular glue-based technology platform that enables therapeutic reactivation of PP2A, a key tumor suppressor enzyme regulating protein de-phosphorylation and tumor growth. The platform leverages proprietary tools, deep understanding of PP2A biology, and high-resolution PP2A-drug complex structural data to develop an entire series of compounds that interlock PP2A subunits and specifically reactivate PP2A's tumor suppressive function. The platform has potential applications across a broad range of human diseases beyond oncology due to PP2A's central role in protein phosphorylation regulation.

Quantifiable outcome

• IND filing targeted by end of 2025 for RPT04402
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• SpringWorks TherapeuticscoreStrategic or Co-development Partner · 13 January 2025Global license agreement for RPT04402, a first-in-class molecular glue targeting the PP2A enzyme for cancer treatment. SpringWorks paid $13 million upfront and will oversee global development and commercialization, including filing an IND application by end of 2025. Rappta remains eligible for clinical, regulatory, and commercial milestone payments plus tiered royalties. The partnership leverages Rappta's proprietary structural data to advance PP2A reactivation as a therapeutic approach.

Scale indicators3 records

Recent moves4 records

Expansion highlights5 records

Direct peers

• Arvinas: Pioneer in targeted protein degradation and molecular glue degraders for oncology. Highly comparable as a fellow molecular-glue-based oncology platform developing first-in-class small molecules, though Arvinas focuses on induced degradation rather than Rappta's PP2A reactivation.
• Monte Rosa Therapeutics: Clinical-stage biotech developing molecular glue degraders for cancer and other diseases. Directly comparable as a molecular-glue platform targeting previously undruggable proteins in oncology, with similar preclinical-to-early-clinical stage assets.
• C4 Therapeutics: Developer of targeted protein degradation therapeutics, including molecular glues, for cancer and other diseases. Comparable as a small-molecule degrader/glue platform focused on oncology, pursuing similar first-in-class opportunities against historically challenging targets.
• Kymera Therapeutics: Clinical-stage biotech focused on targeted protein degradation using heterobifunctional small molecules and molecular glues. Comparable as a fellow modality-platform company developing oncology therapeutics against hard-to-drug targets.

Broad incumbents

• SpringWorks Therapeutics: Rappta's global development and commercialization partner for RPT04402. Comparable as a clinical/commercial-stage oncology company with broader pipeline scope, providing development infrastructure and downstream value capture through milestones and royalties.

Emerging players

• Foghorn Therapeutics: Clinical-stage oncology company developing medicines targeting chromatin biology. Comparable as a platform-based, target-novel small-molecule oncology company using proprietary structural/biological insights to drug previously undruggable targets.
• Repare Therapeutics: Precision oncology company developing synthetic lethality-based therapeutics. Comparable as a small-molecule oncology platform addressing defined genomic-defined patient populations with novel mechanism-of-action drugs.
• Black Diamond Therapeutics: Precision oncology company developing allosteric mutation-targeted therapies. Comparable as a structure-guided oncology platform targeting historically difficult oncogenic drivers with a similar discovery-to-development model.
• Accent Therapeutics: Clinical-stage oncology company developing small-molecule therapies against RNA-modifying proteins. Comparable as an early-stage small-molecule oncology platform pursuing first-in-class mechanism against historically undruggable targets.

Others

• Schrödinger: Computational drug discovery platform company combining physics-based simulation with structure-guided small-molecule design. Comparable as a structure-based drug design platform where high-resolution structural insights drive lead compound development in oncology and other therapeutic areas.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/rappta-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rappta Therapeutics